All In Biotech

Drug Trial Radar · NCT03946449

Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Oct 31, 2019

Primary completion

Apr 28, 2022

Study completion Dec 14, 2023

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver disease (AATD).

Conditions

  • Alpha 1-Antitrypsin Deficiency

Interventions

  • ARO-AATDrug

    solution for subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1bTime frame: Baseline, Week 24
  2. Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 48: Cohort 2Time frame: Baseline, Week 48

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Center 1

    Vienna, Austria

  • Research Center 1

    Aachen, Germany

  • Research Center 3

    Cambridge, United Kingdom

  • Research Center 2

    Edinburgh, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.